1. US Food and Drug Administration. FDA Guidance Concerning Demonstration of Comparability of Human Biological Products, Including Therapeutic Biotechnology-derived Products (FDA, Rockville, MD, April 1996). <
http://www.fda.gov/cder/Guidance/compare.htm
>
2. US Food and Drug Administration. Revised guidance for industry: providing regulatory submissions to the Center for Biologics Evaluation and Research (CBER) in electronic format – biologics marketing applications [Biologics License Application (BLA), Product License Application (PLA)/ Establishment License Application (ELA) and New Drug Application (NDA)] (FDA, Rockville, MD, November 1999). <
http://www.cfsan.fda.gov/~dms/opaegui3.html
>
3. US Food and Drug Administration. Pharmaceutical cGMPs for the 21st century: a risk-based approach (FDA, Rockville, MD, August 2002). <
http://www.fda.gov/oc/guidance/gmp.html
>
4. US Food and Drug Administration. PAT guidance for industry—a framework for innovative pharmaceutical development, manufacturing and quality assurance (US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Veterinary Medicine, Office of Regulatory Affairs, Rockville, MD, September, 2004).
5. Rathore, A.S., Sharma, A. & Chillin, D. BioPharm Int. 19, 48–57 (2006).